AGNOS Study Results Demonstrate Ofatumumab’s Impact on Neurofilament Light, GFAP Marco Meglio

Published Date: 11 Feb 2026

AGNOS trial showed that monthly treatment with ofatumumab lowered NfL and GFAP in patients with early RRMS, signaling reduced nerve damage and bolstering first-line treatment potential.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sub-Q Ketamine is Safe and Very Effective for Severe Depression.

2.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

3.

Contradictory Results Are Found in Two Pembrolizumab Trials for Head and Neck Cancer.

4.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

5.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot